Form 4: Cytek Biosciences CFO Granted Stock Options and Restricted Stock Units
SEC Form 4 Filing
William D. McCombe, CFO of Cytek Biosciences, received stock options and restricted stock units (RSUs) on March 4, 2025, according to a Form 4 filing with the SEC.
Summary
- William D. McCombe, the Chief Financial Officer of Cytek Biosciences, Inc., was granted employee stock options and restricted stock units (RSUs) on March 4, 2025.
- The stock options grant covers 330,882 shares with an exercise price of $4.31 per share, vesting over four years starting April 4, 2025.
- The RSU award covers 208,816 shares, vesting over four years with varying amounts vesting on May 18, August 18, November 18, and March 10 of each year, starting May 18, 2025.
- The filing was signed by Valerie Barnett, Attorney-in-Fact, on March 6, 2025.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral to slightly positive event.
Positives
- The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
- The vesting schedules encourage long-term commitment from the CFO.
Future Outlook
The vesting schedules for both the stock options and RSUs suggest a long-term incentive plan for the CFO.
Industry Context
Granting stock options and RSUs is a common practice in the biotechnology industry to attract and retain key executives and align their interests with those of the shareholders. This is especially true for growth-oriented companies like Cytek Biosciences.
Comparison to Industry Standards
- Stock option and RSU grants are standard compensation components for CFOs in comparable biotech companies.
- Companies like Bio-Rad Laboratories and Agilent Technologies also utilize similar equity-based compensation plans for their executives.
- The vesting schedules are typical, designed to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the transaction (grant of stock options and RSUs) |
| 04/04/2025 | First vesting date for the stock options (1/48 of total shares) |
| 05/18/2025 | First vesting date for the RSU Award (2/48 of total shares) |
| 08/18/2025 | Second vesting date for the RSU Award (3/48 of total shares) |
| 11/18/2025 | Third vesting date for the RSU Award (3/48 of total shares) |
| 03/06/2025 | Date of filing |
| 03/10/2026 | Fourth vesting date for the RSU Award (4/48 of total shares) |
| 03/04/2035 | Expiration date for the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.